Author Correction: MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway

• Chao Fang,
• Yi-Xin Chen,
• Na-Yiyuan Wu,
• Ji-Ye Yin,
• Xiang-Ping Li,
• Hsuan-Shun Huang,
• Wei Zhang,
• Hong-Hao Zhou,
• Zhao-Qian Liu

Affiliations

Chao Fang

Departments of Clinical Pharmacology, Xiangya Hospital, Central South University

Yi-Xin Chen

Departments of Clinical Pharmacology, Xiangya Hospital, Central South University

Na-Yiyuan Wu

Departments of Clinical Pharmacology, Xiangya Hospital, Central South University

Ji-Ye Yin

Departments of Clinical Pharmacology, Xiangya Hospital, Central South University

Xiang-Ping Li

Departments of Pharmacy, Xiangya Hospital, Central South University

Hsuan-Shun Huang

Department of Research, Cervical Cancer Prevention Center, Tzu Chi University

Wei Zhang

Departments of Clinical Pharmacology, Xiangya Hospital, Central South University

Hong-Hao Zhou

Departments of Clinical Pharmacology, Xiangya Hospital, Central South University

Zhao-Qian Liu

Departments of Clinical Pharmacology, Xiangya Hospital, Central South University